RxDoctor Payments Data

Elizabeth Dragan, MD

Neurology · Cincinnati, OHNPI 1982839940

Payments from drug & device makers

$113,809in general payments, 2019–2025

Across 70 payments — averaging $1625.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$100K
  • Biogen$8K
  • Sanofi$3K
  • Genentech, Inc.$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$117
  • plus $338 from 8 others

What the payments were for

  • Consulting fees$4,14066%
  • Food & beverage$1,31821%
  • Education$1012%
  • Gifts$68311%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$113,809 in reported general payments places this provider in the 80th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,006,360
Medicare patients
116
Services billed
22,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a30$267,216
MayzentSiponimod14$156,071
UbrelvyUbrogepant30$32,200
Dalfampridine ErDalfampridine42$24,292
Aimovig AutoinjectorErenumab-Aooe21$14,919
Nurtec OdtRimegepant Sulfate12$12,676
Teriflunomide51$10,613
Topiramate ErTopiramate12$8,476
Dimethyl Fumarate37$4,950
Mycophenolate Mofetil12$4,773
Baclofen129$2,495
FingolimodFingolimod Hcl11$2,344
Oxcarbazepine24$2,106
Modafinil35$1,656
Gabapentin104$1,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$1,249$156,07114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 702 neurology providers in Ohio.

Other neurology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →